Genetic Determinants of Hemodynamic Response to Esmolol

Hadassah Medical Center

Status: Unknown

Conditions: Decrease in Heart Rate Below Baseline Value

Treatments: Drug: esmolol

Study type: Interventional

Funder types: Other

Identifiers

NCT01388036

397-27.05.05

Details and patient eligibility

About

Beta 1 Adrenergic antagonists (beta blockers) have major role in the treatment of CHF, IHD and hypertension. However, there is large interindividual variability in the response to beta blockers.

The hypothesis underlying this study is that genetic differences between individuals will determine the individual response to esmolol, a betablocker that is administered intravenously. Esmolol will be administered intravenously to healthy volunteers, and the effects on heart rate and blood pressure will be monitored. In addition, we will measure plasma renin activity and plasma levels of norepinephrine.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy male and female
• able to understand and sign informed consent

Exclusion criteria

• consumption of any medication
• bradycardia <50 BPM
• hypersensitivity to beta blockers

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Single Blind

---

100 participants in 1 patient group

esmolol infusion

Experimental group

Description:

infusion of esmolol during rest and exercise

Treatment:

Drug: esmolol